NPSA (UK's National Patient Safety Agency) resignation sparks policy speculation:
This article was originally published in Clinica
The UK's National Patient Safety Agency's director of communications, Steve Wedgwood, has resigned. The agency would not comment on speculation that his departure might be associated with the recent debate over policy concerning the publication of raw data on adverse events. "The work of the NPSA is continuing and policy has not changed," said a spokesperson, in response to suggestions that Mr Wedgwood's departure might reflect further discord over this issue. The government recently found itself in deep water over its handling of the damning results of a pilot into adverse event reporting.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.